BIOMAT Database Logo BIOMAT Database Logo

[Changes of 24-h Holter monitor recordings in association with interferon alpha therapy for chronic hepatitis C]. 1998

M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
First Department of Medicine, Hokkaido University, School of Medicine.

We examined cardiovascular complication of interferon (IFN) therapy in 23 patients with chronic hepatitis C who did not have cardiac disease prospectively. Twenty four-h Holter monitor recordings were performed before and during IFN therapy. Seven of these patients (30%) showed abnormalities on their 24-h Holter monitoring recordings. Premature ventricular contraction (PVC) occurred in two patients, intermittent WPW syndrome in one, and ST-T change in four. Only one patient with PVC complained of palpitation. These complications were not severe and immediately after IFN therapy was stopped. There was no correlation between Holter ECG abnormalities and sex, age, quantity of HCV, or 2-5 oligoadenylate synthetase activity. It was suggested that cardiovascular complications caused by IFN therapy occurred more frequently than expected. However, diagnosis of these complications is difficult because most patients have no subjective symptoms and there is scarcely any change in laboratory test results. Careful observation of patients may be required during IFN therapy regardless of cardiovascular symptoms.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015716 Electrocardiography, Ambulatory Method in which prolonged electrocardiographic recordings are made on a portable tape recorder (Holter-type system) or solid-state device ("real-time" system), while the patient undergoes normal daily activities. It is useful in the diagnosis and management of intermittent cardiac arrhythmias and transient myocardial ischemia. Ambulatory Electrocardiography,Electrocardiography, Dynamic,Electrocardiography, Holter,Holter ECG,Holter EKG,Holter Monitoring,Monitoring, Ambulatory Electrocardiographic,Monitoring, Holter,Ambulatory Electrocardiography Monitoring,Dynamic Electrocardiography,Electrocardiography Monitoring, Ambulatory,Holter Electrocardiography,Ambulatory Electrocardiographic Monitoring,ECG, Holter,ECGs, Holter,EKG, Holter,EKGs, Holter,Electrocardiographic Monitoring, Ambulatory,Holter ECGs,Holter EKGs,Monitoring, Ambulatory Electrocardiography
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon
D019698 Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS. Chronic Hepatitis C

Related Publications

M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
Interferon-alpha therapy for children with chronic hepatitis C.
January 1998, Zhonghua Minguo xiao er ke yi xue hui za zhi [Journal]. Zhonghua Minguo xiao er ke yi xue hui,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
Pericarditis after therapy with interferon-alpha for chronic hepatitis C.
January 1999, Clinical rheumatology,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.
January 2004, Medical science monitor : international medical journal of experimental and clinical research,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.
June 1998, Journal of hepatology,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
[alpha-Interferon therapy in chronic hepatitis C evaluated].
July 1996, Der Internist,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
Autoimmunity during alpha-interferon therapy for chronic hepatitis C.
May 1993, Gastroenterologia Japonica,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
Changes in glucose tolerance after interferon-alpha therapy in patients with chronic hepatitis C.
January 1997, Journal of medicine,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy.
October 2007, Clinical practice and epidemiology in mental health : CP & EMH,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
Interferon beta induction/interferon alpha therapy in patients with interferon-resistant chronic hepatitis C.
December 2002, Hepatology research : the official journal of the Japan Society of Hepatology,
M Masutani, and J Suzuki, and T Matsuda, and K Takahashi, and K Ohira, and A Nomura, and A Douchin, and K Sadaoka, and Y Kawakami, and A Miura
[Clinicopathologic observations on chronic hepatitis C therapy with interferon-alpha].
July 2003, Orvosi hetilap,
Copied contents to your clipboard!